TrialEfficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Trial details
- Registry ID
- NCT02200757
- Phase
- Phase 2
Drug research
Aldoxorubicin
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as INNO-206
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung CancerNCT02200757 | IBRX | Phase 2 | Completed | 2017-05-15Actual |
| Phase 3 Study to Treat Patients With Soft Tissue SarcomasNCT02049905 | IBRX | Phase 3 | Completed | 2017-05Actual |
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
Trial details
- Registry ID
- NCT02049905
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |